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Objectives: Inflammatory bowel disease (IBD) poses an increased risk for Clostridium difficile infection (CDI).
Fidaxomicin has demonstrated non-inferiority to vancomycin for initial clinical cure of CDI in patients without IBD; how-
ever, lack of data has caused concerns regarding potential systemic absorption of fidaxomicin in patients with IBD.
Methods: The plasma pharmacokinetics (PK) of fidaxomicin and its primary metabolite OP-1118 were evaluated
in a multicentre, open-label, single-arm, Phase IIIb/IV study enrolling patients with active IBD and CDI. Patients
received fidaxomicin, 200 mg twice daily for 10 days. The primary and secondary endpoints were, respectively,
plasma and stool PK of fidaxomicin and OP-1118 on Days 1, 5 and 10 of treatment. Other secondary endpoints
included safety of fidaxomicin treatment (assessed until Day 180). ClinicalTrials.gov identifier: NCT02437591.
Results: Median Tmax of fidaxomicin and OP-1118 for the PK analysis set (PKAS; 24 patients) was 1–2 h across
Days 1, 5 and 10. Cmax ranges were 1.2–154 ng/mL for fidaxomicin and 4.7–555 ng/mL for OP-1118 across Days
1, 5 and 10 (PKAS). The ranges of concentrations in stool were 17.8–2170lg/g for fidaxomicin and 0–1940lg/g
for OP-1118. Sixty percent (15/25) of patients experienced treatment-emergent adverse events (TEAEs), none of
which led to treatment discontinuation or death.
Conclusions: Maximum fidaxomicin and OP-1118 plasma concentrations observed in this study population sug-
gest no increase in absorption, compared with patients without IBD. Incidence of TEAEs was similar to previous
Phase III trials, suggesting that fidaxomicin is comparatively well tolerated in patients with IBD.
Introduction
Clostridium difficile infection (CDI) causes a substantial healthcare
burden in developed countries.1 Patients with inflammatory bowel
disease (IBD) are at particular risk of developing CDI.2 Following
the onset of CDI, patients with IBD have a greater length of hos-
pital stay, are at greater risk for CDI recurrence and have a higher
mortality rate, compared with patients without IBD.2–4 Notably,
rates of CDI are higher among patients with ulcerative colitis (UC)
and Crohn’s disease (CD) with colonic involvement.5,6
Fidaxomicin, a narrow-spectrum macrocyclic antibiotic, has
been shown in two Phase III trials to be non-inferior to standard
vancomycin for the initial clinical cure of CDI.7,8 Furthermore, fidax-
omicin achieved significantly lower rates of CDI recurrence and
higher rates of sustained clinical cure, compared with vanco-
mycin.7,8 However, patients with IBD were excluded from these
studies. Consequently, only limited data are available on the use
of fidaxomicin in patients with both IBD and CDI.9 It is currently
recommended that fidaxomicin is used with caution in patients
with IBD and CDI,10 owing to uncertainty whether absorption of
VC The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
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fidaxomicin is increased in the presence of the colonic and small
bowel inflammation associated with IBD.
The PROFILE study was designed to evaluate the plasma
pharmacokinetics (PK) of fidaxomicin and its primary metabolite
OP-1118 in patients with IBD and CDI, and explore the safety of
fidaxomicin treatment in these patients.
Patients and methods
Ethics
The study protocol and all amendments were reviewed and approved by
independent Ethics Committees or Institutional Review Boards for each
centre (Table S1, available as Supplementary data at JAC Online). The study
was conducted in accordance with the International Council for
Harmonisation guidelines and the Declaration of Helsinki, and all patients
provided written informed consent.
Study design
This was an open-label, single-arm, Phase IIIb/IV study in patients with IBD
and CDI from 28 sites in nine European countries, conducted between
August 2015 and October 2016. The study duration was 180 days for all
patients and comprised eight visits: three visits during the treatment period
(Days 1–10 inclusive) and five visits during follow-up (Days 11–180 inclu-
sive) (Figure 1). PROFILE is registered with ClinicalTrials.gov, number
NCT02437591.
Participants
Patients aged18 years with active IBD and CDI were included in the study.
The main inclusion criteria were as follows: confirmed diagnosis of IBD for
Scheduled study visits
Day 1
Screening* Treatment period
(Days 1–10)
Blood sampling:
Days 1, 5, 10
Stool sampling:
Screening and Days 1‡, 5, 10 (and any unscheduled visit in case of recurrence or treatment failure)
Follow-up (Days 11–180)
for safety and recurrence
Day 5 Day 10 Day 12† Day 26 Day 40 Day 90 Day 180
Figure 1. Study procedures. *Within 48 h of enrolment. Baseline visit (screening and Day 1) could have been completed on the same day.
†Assessment via telephone. ‡Day 1 stool samples taken no earlier than 12 h after the first dose of fidaxomicin.
Assessed for eligibility (n=26)
Completed treatment period and
included in SAF/mFAS (n=25)
Received allocated intervention (n=25)
• CD patients (n=14)
• UC patients (n=11)
PKAS (n=24)
• CD (n=14)
• UC (n=10)
PKAS-Full Profile (n=14)
• CD (n=8)
• UC (n=6)
Enrolment (n=25)
Inclusion criteria
not met (n=1)*
PK results unavailable
(n=1)
Reduced PK profiling
(n=10)
Figure 2. Patient flow diagram. *CDI not confirmed by local testing.
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Table 1. Patient baseline characteristics (SAF)
Characteristic CD (n"14) UC (n"11) Total (n"25)
Female, n (%) 6 (43) 6 (55) 12 (48)
Race, n (%)
white 13 (100) 9 (90) 22 (96)
Asian 0 1 (10) 1 (4)
missing 1 1 2
Age, years, median (range) 34.5 (19–55) 32.0 (21–81) 32.0 (19–81)
C-reactive protein, mg/L, median (range) 6.80 (0.0–96.3) 8.30 (0.3–89.4) 7.10 (0.0–96.3)
Time since IBD diagnosis, years, median (range) 1.2 (0–28) 6.2 (1–10) 2.9 (0–28)
CD locationa
ileal (L1) 7 (50) NA NA
colonic (L2) 1 (7) NA NA
ileocolonic (L3) 6 (43) NA NA
isolated upper GI 1 (7) NA NA
HBI total score categories, n (%)
5–7 (mild disease) 6 (43) NA NA
8–16 (moderate disease) 6 (43) NA NA
.16 (severe disease) 2 (14) NA NA
UC extent
proctitis (E1) NA 1 (9) NA
left-sided extending to splenic flexure (E2) NA 1 (9) NA
extensive disease (E3) NA 9 (82) NA
Partial Mayo Score total categories, n (%)
2–6 (mild–moderate disease) or a score of 1 due to rectal bleeding NA 9 (82) NA
7 (severe disease) NA 2 (18) NA
IBD symptoms, n (%)
abdominal cramps/pain 13 (93) 10 (91) 23 (92)
diarrhoea 14 (100) 9 (82) 23 (92)
blood in stool 6 (43) 9 (82) 15 (60)
defaecation urgency 7 (50) 9 (82) 16 (64)
weight loss 9 (64) 8 (73) 17 (68)
loss of appetite 9 (64) 6 (55) 15 (60)
fever 3 (21) 1 (9) 4 (16)
fatigue 9 (64) 8 (73) 17 (68)
joint pain 7 (50) 2 (18) 9 (36)
Severe CDI by ESCMID score, n (%) 2 (14) 5 (46) 7 (28)
Marked leucocytosisb, n (%) 2 (14) 2 (18) 4 (16)
Pseudomembranous colitis, n (%) 0 2 (18) 2 (8)
Prior CDIc, n (%) 2 (14) 3 (27) 5 (20)
No. of UBMs per dayd, mean (SD) 6.2 (3.7) 6.6 ( 3.5) 6.4 (3.5)
Antibiotic use within 90 days prior to enrolment, n (%) 4 (29) 8 (73) 12 (48)
for CDI 1 (7) 4 (36) 5 (20)
for conditions other than CDI 3 (21) 7 (64) 10 (40)
Antibiotic use for CDI within 90 days prior to enrolment by preferred WHO name, n (%)
metronidazole 1 (7) 2 (18) 3 (12)
rifaximin 0 1 (9) 1 (4)
vancomycin 0 3 (27) 3 (12)
NA, not applicable; UBM, unformed bowel movement; SAF, all patients who received at least one dose of study drug.
aTwo CD patients (ileal L1 and ileocolonic L3 locations) also had perianal disease. One CD patient had isolated upper GI disease in addition to ileoco-
lonic disease.
bLeucocyte count .15%109/L.
cIn the 90 days prior to enrolment. No patient had .1 episode of CDI during this period.
dIn the 24 h prior to enrolment.
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Table 2. Relevant prior and concurrent medications during fidaxomicin treatment by IBD type (SAF)
Medication intake period
Therapeutic subgroup (ATC level 2)
chemical subgroup (ATC level 4)a
preferred WHO name CD (n"14) UC (n"11) Total (n"25)
Prior medications within 90days of enrolment
Antidiarrhoeals and intestinal anti-inflammatory/anti-infective agents 13 (93) 11 (100) 24 (96)
aminosalicylic acid and similar agents 11 (79) 11 (100) 22 (88)
mesalazine 10 (71) 11 (100) 21 (84)
sulfasalazine 2 (14) 0 2 (8)
antibiotics 1 (7) 4 (36) 5 (20)
nystatin 0 1 (9) 1 (4)
rifaximin 1 (7) 2 (18) 3 (12)
vancomycin 1 (7) 4 (36) 5 (20)
antidiarrhoeal microorganisms 2 (14) 0 2 (8)
Lactobacillus acidophilus 1 (7) 0 1 (4)
Lactobacillus plantarum 1 (7) 0 1 (4)
VSL #3 1 (7) 0 1 (4)
Antibacterials for systemic use 4 (29) 7 (64) 11 (44)
meropenem 1 (7) 0 1 (4)
sulperazon 1 (7) 0 1 (4)
amoxi-clavulanico 0 1 (9) 1 (4)
bactrim 0 1 (9) 1 (4)
ciprofloxacin 3 (21) 3 (27) 6 (24)
moxifloxacin 0 1 (9) 1 (4)
vancomycin 1 (7) 4 (36) 5 (20)
metronidazole 4 (29) 5 (46) 9 (36)
Antimycobacterials 0 1 (9) 1 (4)
rifampicin 0 1 (9) 1 (4)
isoniazid 0 1 (9) 1 (4)
Antimycotics for systemic use 0 1 (9) 1 (4)
nystatin 0 1 (9) 1 (4)
fluconazole 0 1 (9) 1 (4)
Corticosteroids for systemic use 8 (57) 7 (64) 15 (60)
budesonide 3 (21) 1 (9) 4 (16)
dexamethasone 1 (7) 0 1 (4)
hydrocortisone 0 4 (36) 4 (16)
methylprednisolone 1 (7) 4 (36) 5 (20)
prednisolone 5 (36) 1 (9) 6 (24)
prednisone 1 (7) 2 (18) 3 (12)
Immunosuppressants 11 (79) 5 (46) 16 (64)
calcineurin inhibitors 0 2 (18) 2 (8)
ciclosporin 0 2 (18) 2 (8)
other immunosuppressants 8 (57) 4 (36) 12 (48)
azathioprine 7 (50) 4 (36) 11 (44)
methotrexate 2 (14) 0 2 (8)
TNF-a inhibitors 5 (36) 2 (18) 7 (28)
adalimumab 1 (7) 0 1 (4)
golimumab 0 1 (9) 1 (4)
infliximab 4 (29) 2 (18) 6 (24)
Concurrent medications during fidaxomicin treatmentb
Antidiarrhoeals and intestinal anti-inflammatory/anti-infective agents 12 (86) 11 (100) 23 (92)
aminosalicylic acid and similar agents 10 (71) 11 (100) 21 (84)
mesalazine 9 (64) 11 (100) 20 (80)
sulfasalazine 1 (7) 0 1 (4)
Continued
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at least 3 months; active IBD (as recorded at enrolment); and positive con-
firmation of CDI by local standard testing within 48 h prior to enrolment
(Table S2). Active IBD was initially defined by either Partial Mayo Score 2
for patients with UC11 or Harvey–Bradshaw index (HBI) score 5, excluding
points for complications, for patients with CD.12 Following initiation of the
study, the protocol was amended to include a requirement for patients
with UC that at least one point should originate from blood in stool.
Therefore, not all patients with UC have one point originating from blood in
stool at baseline.
Patients were excluded if they had received any CDI therapy for more
than 1 day within 48 h prior to enrolment, or had a diagnosis of toxic mega-
colon. Screening and informed consent were completed within 48 h of
enrolment.
Treatment procedures
Fidaxomicin 200 mg tablets were administered orally, twice daily, from Day
1 (within 24 h of enrolment) to Day 10. Fidaxomicin was administered in ac-
cordance with the current Summary of Product Characteristics.10
Previous and concurrent medications
Prior medication recorded included antibiotic, immunosuppressive or IBD
medication taken within 90 days prior to enrolment. All relevant concurrent
medications were recorded for the duration of the study. Treatment of
underlying IBD during this period was at the discretion of the site investiga-
tor. Owing to their potential impact on the evaluation of study endpoints
and the composition of the gut microbiota, it was recommended to avoid
the following medications throughout the study period: non-study oral
fidaxomicin, metronidazole, vancomycin, oral bacitracin, fusidic acid, rifaxi-
min and rifampicin, nitazoxanide, tigecycline, teicoplanin and prebiotics or
probiotics. It was also recommended to avoid faecal microbiota transplant-
ation throughout the study period.
Blood and stool sampling
Blood samples were taken on Days 1, 5 and 10 (pre-dose and 0.5, 1, 1.5, 2,
3, 4, 5 and 10 h post-dose) for PK analysis at a central laboratory. After re-
view of the cumulative PK data from the first 15 patients to establish Tmax,
subsequent patients enrolled into the study could have a limited PK sam-
pling schedule: full PK profile on Day 1 only and sampling on Days 5 and 10
at pre-dose and at the anticipated Tmax (2+0.5 h).
Stool samples for the measurement of fidaxomicin and OP-1118 concen-
trations were obtained on Day 1 (no earlier than 12 h following first dose of
fidaxomicin), Day 5 and Day 10. These underwent PK analysis at a central la-
boratory. Stool samples obtained at screening were stored at #70C, then
transported to a central laboratory for further assessment. Central laboratory
assessments included toxin A/B ELISA, bacterial culture and C. difficile toxin A/
B PCR screening (BioFire FilmArrayV
R
, GI Panel, bioMe´rieux).
Outcomes
PK
The primary endpoint was the plasma PK of fidaxomicin and OP-1118, in
patients with IBD and CDI, on Days 1, 5 and 10 of treatment. A particular
aim was to compare the maximum observed plasma concentrations in this
patient population with those observed for patients without IBD in previous
Table 2. Continued
Medication intake period
Therapeutic subgroup (ATC level 2)
chemical subgroup (ATC level 4)a
preferred WHO name CD (n"14) UC (n"11) Total (n"25)
Antibacterials for systemic use 0 1 (9) 1 (4)
moxifloxacin 0 1 (9) 1 (4)
Corticosteroids for systemic use 6 (43) 8 (73) 14 (56)
budesonide 2 (14) 1 (9) 3 (12)
hydrocortisone 0 1 (9) 1 (4)
methylprednisolone 1 (7) 5 (46) 6 (24)
prednisolone 2 (14) 3 (27) 5 (20)
prednisone 1 (7) 2 (18) 3 (12)
Immunosuppressants 8 (57) 5 (46) 13 (52)
calcineurin inhibitors 0 1 (9) 1 (4)
ciclosporin 0 1 (9) 1 (4)
other immunosuppressants 7 (50) 4 (36) 11 (44)
azathioprine 6 (43) 4 (36) 10 (40)
methotrexate 1 (7) 0 1 (4)
TNF-a inhibitors 3 (21) 0 3 (12)
adalimumab 1 (7) 0 1 (4)
infliximab 2 (14) 0 2 (8)
ATC, Anatomical Therapeutic Chemical; SAF, all patients who received at least one dose of study drug. A medication which could be classified into sev-
eral therapeutic subgroups (ATC level 2) was programmatically coded to each subgroup without consideration of the indication provided by the
investigator.
aNot shown under the following therapeutic subgroups: antibacterials for systemic use; antimycobacterials; antimycotics for systemic use; antivirals
for systemic use; and corticosteroids for systemic use.
bIncludes up to Day 11 for patients who completed the course on Day 11.
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studies of fidaxomicin.8,13,14 A secondary endpoint was fidaxomicin and
OP-1118 stool concentrations at Days 1, 5 and 10.
Safety
Adverse events (AEs) were recorded from the time of informed consent
until the end of the study (Day 180); AEs arising during the period from the
first dose until 30 days following the end of treatment (EoT) were consid-
ered treatment-emergent AEs (TEAEs). AEs of special interest included:
hypersensitivity to fidaxomicin (angioedema, dyspnoea); gastrointestinal
(GI) haemorrhage; decrease in white blood cell (WBC) count; abnormal liver
or kidney function tests; and QT interval prolongation (assessed using ECG
only in the case of a suspected AE).
Efficacy
Assessment of clinical response to treatment at test of cure (ToC; Day 12,
48–72 h after EoT) was based on investigator assessment using the ESCMID
criteria (Supplementary Methods).15 Patients who did not meet the criteria
for CDI clinical response, as determined by the investigator, remained in the
study for safety assessments. For patients with a CDI clinical response, re-
currence of CDI was defined as re-establishment of diarrhoea after ToC to
an extent (judged by the frequency of unformed bowel movements)
greater than the frequency recorded on Day 12 and requiring further CDI
therapy.
Statistical analyses
It was planned to enrol 40 patients to achieve 30 evaluable patients with ei-
ther measurements of fidaxomicin and OP-1118 Cmax, or plasma concen-
trations at Tmax. The planned sample size was chosen based on the
feasibility of recruiting a sufficient number of patients with IBD to be able to
demonstrate the PK of fidaxomicin in this patient population and was not
based on intended statistical power calculation.
The safety analysis set (SAF) consisted of all enrolled patients who
received at least one dose of study medication. The modified full ana-
lysis set (mFAS) consisted of all enrolled patients who received at least
one dose of study medication and had a valid ToC assessment. The PK
analysis set (PKAS) consisted of patients from the SAF for whom at least
one blood plasma measurement of fidaxomicin and OP-1118 was avail-
able and the PKAS-Full Profile included only those patients from the
PKAS who participated in the full PK sampling profile. Further details of
the statistical methods used are described in the Supplementary
Methods.
Results
Patient characteristics
The planned number of patients intended to be enrolled was not
achieved before the end of the recruitment period (30 April 2016).
Eligible patients were recruited from seven countries and 12 sites:
14 with CD and 11 with UC. All 25 patients completed the full
10 days of fidaxomicin treatment and were included in the SAF
and mFAS (Figure 2). PK results were missing for one patient in the
mFAS; 24 patients were therefore included in the PKAS (14 patients
with CD and 10 with UC), of whom 10 patients underwent reduced
PK profiling. Thus, 14 patients were included in the PKAS-Full
Profile.
Twenty-one of the 25 patients completed the investigational
period (Days 1–180): 3 patients with CD chose to withdraw from
the study and 1 patient with UC was lost to follow-up. Five patients
had a minor protocol deviation: four patients entered the study al-
though the local CDI test was not conducted within 48 h of the first
dose and one patient took two additional (commercially available)
fidaxomicin tablets.
Patient baseline characteristics for the SAF are shown in
Table 1. Most patients were in the category of ‘mild’ or ‘moderate’
disease for CD (12/14; 86%) or ‘mild–moderate disease’ for UC
(9/11; 82%) (Table 1). Two patients with CD and five with UC (7/25;
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Figure 3. Plasma concentration of fidaxomicin by IBD type on (a) Day 1,
(b) Day 5 and (c) Day 10 [PKAS (all patients)]. (a) 23 patients (13 CD, 10
UC) with full PK profile measurements; (b, c) 14 patients (8 CD, 6 UC) with
full profile and 10 patients (6 CD, 4 UC) with reduced PK profile (pre-dose,
2+0.5 h). Data are mean+ SD. SDs have been plotted for all timepoints
where n.1. For three patients with deviations from the visit schedule,
pre-dose samples were collected on a day other than the planned visit
day. Final blood samples for each patient were taken at 10 or 12 h post-
dose; data have therefore been plotted at the respective timepoints.
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28%) had a primary diagnosis of severe CDI based on ESCMID crite-
ria.15 One-fifth (5/25; 20%) of patients had a prior history of one
CDI episode in the 90 days prior to study enrolment.
Antibiotics were used by 12/25 (48%) patients in the 90 days
prior to enrolment (Table 1). Of these, 5/25 (20%) patients received
antibiotics for the treatment of CDI. Antidiarrhoeals and intestinal
anti-inflammatory/anti-infective agents were used by 24/25
(96%) patients in the 90 days prior to enrolment, 23/25 (92%)
patients during the treatment period (Days 1–10 inclusive) and 24/
25 (96%) patients during follow-up [Days 11–180, end of study in-
clusive (Table 2 and Supplementary Table S3)]. Immunosuppres-
sants, including TNF-a inhibitors, were used by 16/25 (64%) of all
patients in the 90 days prior to enrolment and 13/25 (52%) of all
patients concurrently with fidaxomicin treatment (Table 2).
All 25 patients tested positive for CDI by local laboratory assess-
ment at screening. With regard to the further tests conducted at
the central laboratory, results from toxin A/B ELISA were available
for 19 patients, of whom 6 (32%) tested positive for CDI. Of the
remaining 13/19 (68%) patients who were negative for CDI by cen-
tral laboratory toxin A/B ELISA, 4 were confirmed positive both by
anaerobic culture and for toxigenic C. difficile by PCR (BioFire
FilmArray, GI Panel), 1 was confirmed positive by PCR (BioFire
FilmArray, GI Panel) alone and 2 were confirmed positive by anaer-
obic culture alone. A total of 13/19 (68%) patients were therefore
confirmed positive for CDI by both local assessment and at least
one central laboratory test. For the remaining 6/19 patients who
tested negative for CDI by central laboratory toxin A/B ELISA, speci-
mens for further microbiological investigation were not available.
Of the 6/25 patients for whom central laboratory toxin A/B ELISA
results were not available, 2 had anaerobic culture performed
from samples taken approximately (and no earlier than) 12 h after
the first dose of fidaxomicin, 1 of whom was positive.
Fidaxomicin exposure
All enrolled patients completed the treatment period of 10 days,
with a mean total dosage of 4016 mg of fidaxomicin per patient.
One patient with CD missed 1 dose on Day 3, but took all 20 doses
of fidaxomicin, completing the course on Day 11. One patient with
UC took an extra two (commercially available) fidaxomicin tablets
in addition to those prescribed; this patient was excluded from the
PKAS (all patients) and PKAS-Full Profile.
PK
Missing PK samples
A pre-dose sample was missing from the full PK profiles of Day 1
for a single patient; this had no implications for the PK analysis. For
one patient with a reduced profile, the 2 h sample at Day 5 was
missing and no Cmax or Tmax could be estimated. One pre-dose
sample on Day 10 from a patient with a reduced profile was also
missing; no Ctrough could be estimated for this patient.
Table 3. Plasma PK parameters of fidaxomicin and OP-1118 [PKAS (all patients) and PKAS-Full Profile]
Fidaxomicin OP-1118
PKAS (all patients) PKAS-Full Profile PKAS (all patients) PKAS-Full Profile
Day Parameter
Ctrough
(ng/mL)
Cmax
(ng/mL)
Cmax
(ng/mL) Tmax (h)
AUCa
(ngh/mL)
Ctrough
(ng/mL)
Cmax
(ng/mL)
Cmax
(ng/mL) Tmax (h)
AUCa
(ngh/mL)
1 n 23 14 14 8 — 23 14 14 9
median — 9.7 9.9 1.8 67.6 — 24.7 23.7 1.8 169.0
min–max 2.5–75.3 3.4–75.3 0.5–11.5 22.7–339 — 4.9–336 10.3–336 0.5–11.5 36.2–1550
mean (SD) — 14.6 (16.1) 17.9 (19.8) 2.5 (2.8) 98.3 (102.2) — 45.3 (67.5) 57.5 (84.7) 2.6 (2.9) 323.0 (482.4)
5 n 23 23 13 13 11 23 23 13 13 10
median 4.3 12.2 17.7 1.0 116.5 12.7 42.7 45.8 1.0 415.5
min–max 0.7–28.8 1.2–154 5.3–154 0.5–3.0 38.0–513 2.3–88.9 4.7–555 15.2–555 0.5–5.0 102–2269
mean (SD) 6.2 (6.5) 20.3 (31.8) 30.0 (40.1) 1.3 (0.7) 155.6 (150.9) 22.1 (22.2) 70.3 (116.7) 99.0 (149.5) 1.5 (1.3) 668.7 (726.0)
10 n 22 24 14 14 11 22 24 14 14 12
median, 3.3 11.3 13.4 1.8 109.8 13.6 45.5 45.8 2.0 301.4
min–max 1.0–11.6 4.6–71.3 4.6–71.3 0–5.4 19.2–364 2.5–62.8 10.6–206 10.6–206 0–5.4 52.8–1161
mean (SD) 4.4 (3.2) 16.3 (15.1) 20.2 (18.6) 2.2 (1.7) 129.1 (115.0) 18.2 (15.6) 53.1 (43.5) 61.5 (52.0) 2.4 (1.7) 389.1 (364.7)
Max across
days
median — 14.6 — — — — 46.1 — — —
min–max — 5.75–154 — — — — 13.5–555 — — —
mean (SD) 22.6 (30.4) — — — — 78.5 (111.6) — — —
PKAS (all patients), patients from the SAF for whom at least one blood plasma measurement of fidaxomicin and OP-1118 was available; PKAS-Full
Profile, including only those patients from the PKAS who participated in the full PK sampling profile. PKAS (all patients) and PKAS-Full Profile exclude
the one patient with UC who took an extra two (commercially available) fidaxomicin tablets in addition to those prescribed.
aAUC12 (from the time of dosing to 12 h post-dose), Day 1; AUCtau (from the time of dosing to the start of the next dosing interval), Days 5 and 10. As
fidaxomicin is minimally absorbed and the Tmax is variable, the terminal t1=2 and AUC could not be estimated in all cases; additional comparisons
showed no resultant bias.
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Fidaxomicin plasma concentrations
The mean plasma concentrations of fidaxomicin for all 24 patients
in the PKAS are given in Figure 3 and the fidaxomicin PK parameters
are provided in Table 3. The median Tmax across all days was1–2 h,
but varied widely between 0 and 11.5 h (Table 3 and Figure 3). On
Day 5 in patients with UC, an additional earlier peak was observed
at approximately 1.5 h after fidaxomicin dosing (Figure 3).
The median plasma Cmax across all days for the PKAS was
14.6 ng/mL (range 5.8–154 ng/mL). No apparent differences in
plasma Cmax were observed between patients with a limited PK
profile and those with a full profile. The highest observed plasma
Cmax were all from one patient with UC who had relatively high
fidaxomicin concentrations throughout the study period (Day 1,
75.3 ng/mL; Day 5, 154 ng/mL; Day 10, 71.3 ng/mL).
OP-1118 plasma concentrations
Mean plasma concentration–time profiles of OP-1118 (Figure 4)
were similar to those of fidaxomicin. Overall, the observed plasma
concentrations of OP-1118 were 2–6-fold higher than those of
fidaxomicin.
PK parameters of OP-1118 are given in Table 3 and Cmax
measurements by IBD type are given in Table 4. The median
Cmax for the PKAS across Days 1, 5 and 10 was 46.1 ng/mL
(range 13.5–555 ng/mL). The highest observed plasma Cmax
values for OP-1118 (Day 1, 336 ng/mL; Day 5, 555 ng/mL; Day 10,
206 ng/mL) were all from the same patient with UC who also expe-
rienced the highest fidaxomicin plasma concentrations.
Stool concentrations of fidaxomicin and OP-1118
The mean concentrations of fidaxomicin and OP-1118 in stool
samples rose over the treatment period (Table 5). Median fidaxo-
micin concentrations increased from 217.0lg/g on Day 1 to
692.5lg/g on Day 10 and median OP-1118 concentrations
increased from 116.0lg/g on Day 1 to 370.5lg/g on Day 10. For
the one patient with UC who had the highest fidaxomicin and OP-
1118 plasma Cmax, stool concentrations of fidaxomicin were
221lg/g on Day 5 and 415lg/g on Day 10, and OP-1118 concen-
trations were 132lg/g on Day 5 and 434lg/g on Day 10 (no Day 1
post-first-dose sample was available).
Safety
AEs
Of patients in the SAF set, 15/25 (60%) experienced TEAEs within
30 days after EoT (Table S4). The majority (35/43, 81%) of TEAEs
were mild or moderate. Of 25 patients, 10 (40%) experienced a
total of 19 drug-related TEAEs (Table S4). There were no TEAEs or
drug-related TEAEs that resulted in permanent discontinuation of
the study drug. Serious TEAEs (n"8) were experienced by 6/25
(24%) patients, half of which were GI related (Table S4).
Two (8%) patients experienced serious drug-related TEAEs
(Table S4). Of these, one patient experienced severe hypoxia on
Day 40, which subsequently resolved on Day 58. This was judged
by the investigator to be possibly related to both fidaxomicin and
treatment with infliximab for IBD flare-ups, as the patient had
received infliximab both before and after the fidaxomicin treat-
ment period. One patient developed a severe skin ulcer starting
on Day 24; the event resolved on Day 54 and was considered
by the investigator to be possibly related to treatment with
fidaxomicin.
Six (24%) patients had an AE of special interest (Table S4). Of
these, one patient with UC had elevated ALT at baseline (91 U/L)
and throughout the treatment period, but resolved at Day 86
(20 U/L) after the withdrawal of concomitant azathioprine; this
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Figure 4. Plasma concentration of OP-1118 by IBD type on (a) Day 1, (b)
Day 5 and (c) Day 10 [PKAS (all patients)]. (a) 23 patients (13 CD, 10 UC)
with full PK profile measurements; (b, c) 14 patients (8 CD, 6 UC) with full
profile and 10 patients (6 CD, 4 UC) with reduced PK profile (pre-dose,
2+0.5 h). Data are mean+ SD. SDs have been plotted for all timepoints
where n.1. For three patients with deviations from the visit schedule,
pre-dose samples were collected on a day other than the planned visit
day. Final blood samples for each patient were taken at 10 or 12 h post-
dose; data have therefore been plotted at the respective timepoints.
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event was considered unrelated to fidaxomicin treatment. There
were no instances of hypersensitivity to fidaxomicin or of QT inter-
val prolongation.
During long-term follow-up .30 days after EoT, 11/25 (44%)
patients reported 50 AEs. The majority of these events were GI
related. One event experienced by 1/25 (4%) patients was consid-
ered possibly related to fidaxomicin (ulnar nerve injury). Serious
AEs (n"11) were experienced by 7/25 (28%) patients, but none
was considered to be related to fidaxomicin. There were no deaths
during the study.
Clinical laboratory evaluations and vital signs
Most patients were within the normal reference ranges for haem-
atological, biochemistry, WBC and neutrophil counts (Table S5).
No notable changes were observed in blood pressure, temperature
or pulse rate throughout the study.
Efficacy
Of all patients in the mFAS, 20/25 (80%) patients experienced clin-
ical response according to ESCMID criteria at Day 12: 9/14 (64%)
Table 4. Plasma Cmax of fidaxomicin and OP-1118 by IBD type [PKAS (all patients)]
Fidaxomicin Cmax (ng/mL) OP-1118 Cmax (ng/mL)
Day Parameter CD UC total CD UC total
1 n 13 10 23 13 10 23
median 7.4 10.9 9.7 22.4 25.6 24.7
min–max 2.5–25.9 6.1–75.3 2.5–75.3 4.9–84.7 15.6–336 4.9–336
mean (SD) 9.9 (6.7) 20.7 (22.4) 14.6 (16.1) 30.3 (23.3) 64.7 (98.3) 45.3 (67.5)
5 n 13 10 23 13 10 23
median 12.4 11.4 12.2 37.0 44.3 42.7
min–max 2.2–28.2 1.2–154 1.2–154 5.7–99.4 4.7–555 4.7–555
mean (SD) 13.1 (7.4) 29.8 (47.1) 20.3 (31.8) 42.8 (28.4) 106.0 (172.4) 70.3 (116.7)
10 n 14 10 24 14 10 24
median 11.0 16.1 11.3 38.4 48.1 45.5
min–max 4.6–33.5 5.8–71.3 4.6–71.3 10.6–94.7 12.3–206 10.6–206
mean (SD) 12.1 (7.7) 22.0 (20.7) 16.3 (15.1) 41.6 (26.5) 69.3 (57.7) 53.1 (43.5)
PKAS (all patients), patients from the SAF for whom at least one blood plasma measurement of fidaxomicin and OP-1118 was available; PKAS-Full
Profile, including only those patients from the PKAS who participated in the full PK sampling profile. PKAS (all patients) and PKAS-Full Profile exclude
the one patient with UC who took an extra two (commercially available) fidaxomicin tablets in addition to those prescribed.
Table 5. Stool concentrations of fidaxomicin and OP-1118 on Days 1, 5 and 10 by IBD type [PKAS (all patients)]
Fidaxomicin (lg/g) OP-1118 (lg/g)
Day Parameter CD UC total CD UC total
1a n 5 2 7 5 2 7
median 217.0 196.9 217.0 116.0 85.0 116.0
min–max 36.0–804.0 17.8–376.0 17.8–804.0 0.0–318.0 0.0–170.0 0.0–318.0
mean (SD) 348.8 (341.2) 196.9 (253.3) 305.4 (306.2) 143.5 (134.0) 85.0 (120.2) 126.8 (123.3)
5 n 12 9 21 12 9 21
median 778.0 621.0 697.0 470.0 268.0 395.0
min–max 403.0–1640 42.1–1240 42.1–1640 198.0–1940 26.6–662.0 26.6–1940
mean (SD) 840.5 (397.6) 628.8 (418.6) 749.8 (410.5) 618.1 (492.9) 331.5 (234.8) 495.3 (420.5)
10 n 13 9 22 13 9 22
median 564.0 821.0 692.5 287.0 434.0 370.5
min–max 162.0–2170 71.4–1570 71.4–2170 25.9–1830 82.2–777.0 25.9–1830
mean (SD) 894.2 (687.7) 772.7 (520.9) 844.5 (614.3) 496.3 (558.3) 424.6 (241.2) 467.0 (449.0)
PKAS (all patients), patients from the SAF for whom at least one blood plasma measurement of fidaxomicin and OP-1118 was available; PKAS-Full
Profile, including only those patients from the PKAS who participated in the full PK sampling profile. PKAS (all patients) and PKAS-Full Profile exclude
the one patient with UC who took an extra two (commercially available) fidaxomicin tablets in addition to those prescribed. Concentrations below the
limit of quantification (10 ng/mL of diluted stool homogenate or about 2lg/g stool concentrations) were set to zero.
aOn Day 1, a total of 18 stool samples were collected, but only results for the 7 samples collected in the protocol-specified time period (.12 h) post-
dose are included.
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patients with CD and 11/11 (100%) of patients with UC (Table 6).
One patient with CD (13%, 1/8) and two with UC (20%, 2/10) expe-
rienced recurrence of CDI.
Discussion
To date, the use of fidaxomicin in patients with CDI and IBD has
been described only in retrospective studies9 and data regarding
the safety and utility of fidaxomicin in these patients are limited.
There is an unmet need to explore the PK profile of fidaxomicin in
patients with IBD and to determine whether chronic intestinal in-
flammation and disturbance of GI barriers alter the absorption of
the drug. The current investigation is, to our knowledge, the first
prospective study of fidaxomicin in patients with IBD and CDI, and
the first to explore fidaxomicin PK in this setting.
Previous analysis in patients with CDI and no IBD confirmed
that fidaxomicin has minimal systemic absorption and the plasma
concentrations of the parent drug and its primary metabolite re-
main low throughout the dosing period.13 In this study, maximum
plasma concentrations of fidaxomicin and OP-1118 in patients
with active IBD and CDI were within the measured ranges of con-
centrations found in patients with CDI, but without IBD.8,13,14 This
suggests no increase in absorption of fidaxomicin or OP-1118 in
patients with active IBD. Based on AUC and Cmax results across
Days 1, 5 and 10, there was no evidence of accumulation of fidaxo-
micin or OP-1118 in plasma over the treatment period. The max-
imum measured plasma concentration of fidaxomicin was
154 ng/mL, well below the human equivalent of the no-observed-
adverse-effect limit of 3000 ng/mL extrapolated from dog toxicol-
ogy studies.16 The Cmax of 154 ng/mL was observed in a patient
with UC who had relatively high plasma concentrations through-
out the study period, compared with other patients in the study.
The median plasma Cmax of fidaxomicin and OP-1118 were there-
fore slightly higher in the subgroup of patients with UC compared
with patients with CD; median plasma Cmax values obtained from
the PKAS-Full Profile were also slightly higher compared with
plasma Cmax from the PKAS (all patients), due to the inclusion of
this patient in the PKAS-Full Profile. Of note, the patient with UC
who experienced the highest fidaxomicin and OP-1118 plasma
concentrations had a Partial Mayo Score of 5 at baseline, within
the range of disease severity recorded in the subgroup of patients
with UC.
The concentrations of fidaxomicin and OP-1118 found in stool
were lower in our study compared with a previous clinical trial of
patients without IBD.13 However, it should be noted that for both
fidaxomicin and OP-1118, there was substantial variability be-
tween patients in our study; relatively high standard deviations
were also observed in the previous trial.13 Nevertheless, stool con-
centrations of fidaxomicin and OP-1118 consistently attained
supra-therapeutic levels in excess of the MIC for C. difficile.
The ClosER surveillance study,17 which analysed 2694 C. difficile
isolates between 2011 and 2014, determined that the MIC90 (the
lowest concentration at which the growth of 90% of isolates was
inhibited) of fidaxomicin for C. difficile was 0.125 mg/L. Mean stool
concentrations of fidaxomicin observed in the IBD patient popula-
tion in the present study ranged from 305.4lg/g on Day 1 to
844.5lg/g on Day 10, which (assuming a stool density of1 g/mL)
were well in excess of the MIC90 for C. difficile.
Our PK findings are also supported by the accompanying safety
data. Although we expected some AEs to be associated with the
underlying active IBD, overall incidences of TEAEs (60%) and ser-
ious TEAEs (24%) observed in this study were similar to those
observed during previous Phase III trials in patients with CDI, but
no IBD.7,8 The majority of AEs were mild or moderate in severity
and there were no cases of hypersensitivity to fidaxomicin or AEs
that resulted in discontinuation of treatment. Incidence of drug-
related TEAEs (40%) was higher than that reported by Cornely
et al.7 (11.7%), although the assessment period was longer in the
present study. Two serious AEs reported within 30 days after EoT
(hypoxia and skin ulcer) were assessed by the investigator as pos-
sibly related to fidaxomicin treatment; however, there is no other
pre-clinical or clinical evidence to suggest a causal association of
these events with fidaxomicin. There were no deaths during this
study and the clinical laboratory evaluations conducted suggested
no safety concerns regarding the use of fidaxomicin in patients
with IBD.
Regarding limitations, this study was an uncontrolled study in
which all patients had both IBD and CDI. The sample size was small
and was chosen based on clinical and practical considerations
with the aim of obtaining a sufficient number of evaluable PK pro-
files. The age range of patients enrolled (range 19–81 years)
included a relatively young population, with only three patients
older than 65 years; additional studies may therefore be required
to ascertain safety in patients older than 65 years, who are at high-
est risk of CDI complications.15,18,19
Furthermore, the diagnosis of CDI poses particular challenges in
patients with IBD, partly due to the overlap in clinical presentation
of the two diseases.20 Individual diagnostic tests can also produce
Table 6. Clinical outcomes by IBD type (mFAS)
Clinical outcome, n (%) CD (N"14) UC (N"11) Total (N"25)
Clinical response at Day 12 9/14 (64) 11/11 (100) 20/25 (80)
Clinical failure at Day 12 5/14 (36) 0 5/25 (20)
Sustained clinical cure at Day 180 7/9 (78) 8/11 (73) 15/20 (75)
Cumulative recurrencea until Day 180 1/8 (13)b 2/10 (20)c 3/18 (17)b,c
n, number of observations; N, number of patients.
aRelapse or reinfection.
bExcludes one patient with CD who discontinued on Day 28 with sustained clinical cure.
cExcludes one patient with UC who discontinued on Day 91 with sustained clinical cure.
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differing results: in our study, 7/13 patients with a negative central
laboratory toxin A/B ELISA were confirmed positive for CDI by add-
itional PCR and/or anaerobic culture. Moreover, in the present
study, there were proportionally more patients with severe CDI (by
ESCMID score) among those with UC than CD. All the patients with
UC had a clinical response and it remains to be determined
whether, in patients with UC, C. difficile positivity has a more pro-
nounced impact on symptoms than in patients with CD.
In conclusion, the PK properties of fidaxomicin and OP-1118 in
this study of patients with IBD and CDI suggest no increase in ab-
sorption of the parent drug or its primary metabolite, compared
with previously published results from patients with CDI and no
IBD. The similarity of the AE profiles in this study to those previously
observed in patients without IBD suggest that fidaxomicin is com-
paratively well tolerated in this patient population.
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